Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-18
2011-01-18
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S220000, C549S467000
Reexamination Certificate
active
07872044
ABSTRACT:
The present invention is directed to a compound of Formula (I):or an enantiomer, diastereomer, polymorph or pharmaceutically acceptable salt thereof and methods for preparing said compounds and compositions, intermediates and derivatives thereof, and methods for treating inflammatory or serine protease mediated disorders.
REFERENCES:
patent: 5508273 (1996-04-01), Beers et al.
patent: 2005/0176769 (2005-08-01), Hawkins et al.
patent: 0661260 (1995-07-01), None
patent: 1399089 (1971-05-01), None
patent: WO 2005/073214 (2005-08-01), None
patent: WO 2005/073214 (2005-08-01), None
Rouhi, Chemical and Engineering News (2003) pp. 32-35.
U.S. Appl. No. 11/037,938, filed Jan. 18, 2005, Hawkins et al.
Schwender et al, “1-Naphthylmethylphosphonic Acid Derivatives as Osteoclastic Acid Phosphatase Inhibitors,” Bioorganic and Medicinal Chemistry Letters, 1995, pp. 1801-1806, vol. 5, No. 16, Elsevier Science, LTD, Great Britain.
Deprele et al, “A Novel and Conveneient Preparation of Hypophosphite Esters,” Journal of Organo Metallic Chemistry, 2002, pp. 154-163, 643-644, Elsevier Science.
De Lombaert et al, “Non-Peptide Inhibitors of Neutral Endopeptidase 24.11 2. Design and Pharmacology Oforally Active Phosphonate Prodrugs,” Bioorganic & Medicinal Chemistry Letters, 1995, pp. 151-154, vol. 5, No. 2, Elsevier Science, Ltd., Great Britain.
De Lombaert et al, “N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, A New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors,” J. Med. Chem., 1994, pp. 498-511, American Chemical Society.
Longley et al, “Chymase Cleavage of Stem Cell Factor Yields a Bioactive Soluble Product,” Proc Natl Acad Science, 1997, pp. 9017-9021, vol. 94, Biochemistry, USA.
Takai et al, “Application of a Chymase Inhibitor, NK3201, for Prevention of Vascular Proliferation,” Cardiovascular Drug Reviews, 2003, pp. 185-198, vol. 21, No. 3, Neva Press, USA.
Ehara et al, “Contribution of Mast Cells to the Tubulointerstitial Lesions in Iganephritis,” Kidney International, 1998, pp. 1675-1683, vol. 54, International Society of Nephrology.
Okamoto et al, “Chymase Inhibitor, BCEAB, Suppressed Peritoneal Adhesion Formation in Hamster,” Journal of Surgical Research, 2002, pp. 219-222, vol. 107, Elsevier Science, USA.
Yao et al, “Association Between the Expression of Mast Cell Chymase and Intraperitoneal Adhesion Formation in Mice,” Journal of Surgical Research, 2000, pp. 40-44, vol. 92, Academic Press.
Paananen et al, “Proteolysis and Fusion of Low Density Lipoprotein Particles Independently Strengthen Their Binding to Exocytosed Mast Cell Granules,” The Journal of Biological Chemistry, 1994, pp. 2023-2031, vol. 269, No. 3, The American Society for Biochemistry and Molecular Biology, Inc., USA.
Lindstedt et al, “Chymase in Exocytosed Rat Mast Cell Granules Effectively Proteolyzes Apolipoprotein Al-Containing Lipoproteins, so Reducing the Cholesterol Efflux-Inducing Ability of Serum and Aortic Intimal Fluid,” J. Clin Invest., 1996. pp. 2174-2182, vol. 97, No. 10, The American Society for Clinical Investigation, Inc.
Matsumoto et al, “Chymase Inhibition Prevents Cardiac Fibrosis and Improves Disatolic Dysfunction in the Progression of Heart Failure,” Circulation, 2003, pp. 2555-2558, vol. 107.
Katritzky et al, “A One-Pot Procedure for the Preparation of Phosphoic Acids From Alkyl Halides,” Organic Preparations and Procedures Int., 1990, pp. 209-213, vol. 22, No. 2.
Belley et al, “Synthesis of the Nanomolar Photoaffinity GABAbReceptor Ligand CGP 71872 Reveals Diversity in the Tissue Distribution of GABAbReceptor Forms,” Bioorganic & Medicinal Chemistry, 1999, pp. 2697-2704, 7, Elsevier Science Ltd.
Deprele et al, “Palladium-Catalyzed Hydrophosphinylation of Alkenes and Alkynes,” J. Am. Chem. Soc., 2002, pp. 9386-9387, American Chemical Society.
Henke et al, “Optimization of 3-(1H-Indazol-3-Ylmethyl)—1.5 Benzodiazepines as Potent, Orally Active CCK-A Agonists,” J. Med. Chem, 1997, pp. 2706-2725, vol. 40, American Chemical Society.
Steininger et al, Chem Ber, 1963, pp. 3184-3194.
Froestl et al, “Phosphonic Acid Analyogues of GABA 1. New Potent and Selective GABAbAgonists,” j med. Chem.., 1995, pp. 3297-3312, vol. 38.
Yamashiro et al, “Distributino of Intrahepatic Mast Cells in Various Hepatobiliary Disorders,” Virchows Arch, 1998, pp. 471-479, vol. 433.
Design of Prodrugs, Ed. H. Bundgaard, Elsevier, 1985.
Protective Groups in Organic Cheemistry, Ed. J.F.W.McOmie, Plenum Press, 1973.
T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991.
Garabadzhiu et al, “Reactions of Perfluoroalkyl Iodides With Phosphorus (III) Esters, V. Kinetics and Mechanism of the Reactions of Heptafluoropropyl Iodide With Ethylphosphonous Esters,” Journal of General Chemistry USSR—Eng Translation Version 1981, 1905-10, ISSN 00221279, The British Library.
Depaulis et al, “Novel Autocrine and Paracrine Loops of the Stem Cell Factor/Chymase Network,” int arch allergy immunol, 1999, pp. 422-425, vol. 118.
Hara et al, “Evidence for a Role of Mast Cells in the Evolution to Confestive Heart Failure,” J. Exp. Med., 2002, pp. 375-381, vol. 195, No. 3.
Lucas et al, “Formation of Abdominal Adhesions is Inhibited by Antibodies to Transforming Growth Factor-β1,” Journal of Surgical Research, 1996, pp. 135-138, vol. 65, Academic Press.
Gotis-Graham et al.,“Mast Cell Responses in Rheumatoid Synovium: Association of the MC sub TC subset with Matrix Turnover and Clinical Progession,” 1997, pp. 479-489, vol. 40 (3), American College of Rheumagtology.
Gould et al., “Salt Selection for basic drugs,”International Journal of Pharmaceutics, 1986, pp. 201-217, vol. 33, Elsevier Science Publishers B.V.
Graham et al., “Topically Active Carbonic Anhydrase Inhibitors,” J Med. Chem, 1989, pp. 2548-2554, vol. 32, No. 12, American Chemical Society.
Egfange et al., “Modified Ibogaine Fragments: Synthesis and Preliminary Pharmacological characterization of 3-Ethyl-5-phenly-1,2,3,4,5,6- hexahydroazepino[4,5-b] benzothiophenes,” J Med Chem, 1998, pp. 4486-4491, vol. 41, American Chemical Society.
Ple et al., “Synthesis of Substituted Benzo [b]thiophenes by Acid-Catalyzed Cyclizagtion of Thiophenylacetals and Ketones,” J. Heterocyclic Chem, 1988, pp. 1271, 25.
Steininger, “Uber die Herstellung von Bis-phosphiinigsaureestern and anderer Bix-phosphorverbindungen,” Chem Berg, 1963, pp. 3184-3194, 96.
Cory et al, “Extended Chains of Six-Membered Rings 1. Model Studies and Key Intermediates,” Synthetic Communications, 1994, pp. 799-807, vol. 24, No. 6 Marcel Dekker, Inc.
Michele Rebound-Ravaux et al, Journal De La Societe De Biologie, ISSN 1295-0661, 2001, pp. 143-150, vol. 195, No. 2.
Matsumoto et al., “Chymase Inhibition Prevents Cardiac Fibrosis and Improves Diastolic Dysfunction in the Progression of heart Failure,” Circulation, pp. 2555-2558.
Denney et al., “Isomeric five-Membered ring Phophites and Phosphates” Journal of the American Chemical society, 1969, pp. 6838-6841, vol. 91, 24.
Grasa et al., “Amination Reactions of Aryl halides with Nitrogen-Containing reagents Mediated by Palladium/Imidazolium salts Systems,” J Org Chem, pp. 7729-7737, vol. 66.
Belley et al., “Synthesis of the Nanomolar Photoaffinity GABABReceptor Ligand CGP 71872 Reveals Diveristy in the Tissue distribution of GFABABreceptor forms,” Biorganic and Medicinal Chemistry, 1999, pp. 2697-2704, vol. 7, Elsevier Science Ltd.
Martinez et al, “New 3-[4-(aryl)piperazin-1-yl]-1-(benzo[b]thiophen-3-yl) propane derivatives with dual action at 5-HT1Aserotonin receptors and serotonin transporter as a new class of antidepressants,ȁ
Greco Michael
Hawkins Michael
Maryanoff Bruce E.
Powell Eugene
Anderson Rebecca L
Janssen Pharmaceutica NV
Stercho Yuriy P.
Young Shawquia
LandOfFree
Inhibitors of chymase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of chymase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of chymase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2740080